Partner Fund Management, L.P.
13F Reported Value
ⓘ$1.1B
incl. option notional
Equity Holdings
ⓘ$950.2M
Option Notional
ⓘ$146.5M
$87.6M puts / $58.9M calls
Holdings
83
Latest Filing
2026-03-31
Filing Quarter
Q1 2026
Portfolio Overview
Partner Fund Management, L.P. disclosed 83 positions worth $1.1B in its Form 13F-HR for Q1 2026 — $950.2M in common stock plus $146.5M of put/call option positions (reported at underlying notional value, not premium at risk), led by $THC (TENET HEALTHCARE CORP) at 7.9% of the equity portfolio, followed by $LLY. During the quarter the fund opened 24 new positions and exited 19 and a full exit from $ADMA. The portfolio is most concentrated in Healthcare (95.5% of disclosed assets). All figures are sourced directly from Partner Fund Management, L.P.’s Form 13F-HR filing with the SEC under CIK 1442756.
AI Fund Analysis
StableSector Allocation
AUM History
Top Equity Holdings by Value
Option Positions
13F rules report options at the value of the underlying shares (notional) — not the premium paid or capital at risk. Shown separately from the equity sleeve above.
Quarterly Activity — Q1 2026
Click any card to unlockTop Holdings
- 66.6#510
Quality
$75.2M398,567 sh - 89.3#2
Quality
$60.5M65,762 sh SPDR SERIES TRUST PUT
—Quality
$58.2M455,300 sh- 69.7
Quality
$45.9M139,779 sh - 36.6
Quality
$44.7M264,304 sh SELECT SECTOR SPDR TR CALL
—Quality
$35.0M238,900 sh- 41.5
Quality
$34.8M152,034 sh - —
Quality
$33.7M178,144 sh - 75.4
Quality
$28.4M215,678 sh - 80.1
Quality
$27.2M45,900 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 TENET HEALTHCARE CORP$THC | 66.6#510 | $75.2M | 398,567 |
 ELI LILLY & Co$LLY | 89.3#2 | $60.5M | 65,762 |
| SPDR SERIES TRUST PUT | — | $58.2M | 455,300 |
 Penumbra Inc$PEN | 69.7 | $45.9M | 139,779 |
 Axsome Therapeutics, Inc.$AXSM | 36.6 | $44.7M | 264,304 |
| SELECT SECTOR SPDR TR CALL | — | $35.0M | 238,900 |
 Ascendis Pharma A/S$ASND | 41.5 | $34.8M | 152,034 |
 Jazz Pharmaceuticals plc$JAZZ | — | $33.7M | 178,144 |
 NEUROCRINE BIOSCIENCES INC$NBIX | 75.4 | $28.4M | 215,678 |
 UNITED THERAPEUTICS Corp$UTHRPUT | 80.1 | $27.2M | 45,900 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Partner Fund Management, L.P.'s 83 positions.
Showing top 10 of 83 holdings.
Sector Allocation
Healthcare
$907.6M
Technology
$35.9M
Consumer Staples
$6.7M
Full Holdings — Partner Fund Management, L.P. (Q1 2026)
All 83 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $THC | TENET HEALTHCARE CORP | $75.2M | 7.9% | +0% | 66.6 |
| 2 | $LLY | ELI LILLY & Co | $60.5M | 6.4% | -4% | 89.3 |
| 3 | — | SPDR SERIES TRUST | $58.2M | — | NEW | — |
| 4 | $PEN | Penumbra Inc | $45.9M | 4.8% | -4% | 69.7 |
| 5 | $AXSM | Axsome Therapeutics, Inc. | $44.7M | 4.7% | +5% | 36.6 |
| 6 | — | SELECT SECTOR SPDR TR | $35.0M | — | NEW | — |
| 7 | $ASND | Ascendis Pharma A/S | $34.8M | 3.7% | -14% | 41.5 |
| 8 | $JAZZ | Jazz Pharmaceuticals plc | $33.7M | 3.5% | +253% | — |
| 9 | $NBIX | NEUROCRINE BIOSCIENCES INC | $28.4M | 3.0% | +32% | 75.4 |
| 10 | $UTHRPUT | UNITED THERAPEUTICS Corp | $27.2M | — | NEW | 80.1 |
| 11 | $UTHR | UNITED THERAPEUTICS Corp | $23.6M | 2.5% | -41% | 80.1 |
| 12 |  $GKOS | GLAUKOS Corp | $23.2M | 2.4% | +7% | 39.2 |
| 13 |  $CNTA | Centessa Pharmaceuticals plc | $21.0M | 2.2% | -11% | — |
| 14 |  $INBX | Inhibrx Biosciences, Inc. | $20.5M | 2.2% | +15% | 3.1 |
| 15 |  $EW | Edwards Lifesciences Corp | $20.4M | 2.1% | +3% | 67.6 |
| 16 |  $BBIO | BridgeBio Pharma, Inc. | $19.1M | 2.0% | -16% | 31.7 |
| 17 | $UTHRCALL | UNITED THERAPEUTICS Corp | $18.8M | — | NEW | 80.1 |
| 18 |  $MDGL | MADRIGAL PHARMACEUTICALS, INC. | $17.9M | 1.9% | +370% | 25.4 |
| 19 |  $INDV | Indivior Pharmaceuticals, Inc. | $17.5M | 1.8% | +59% | 64.6 |
| 20 | $ASND | Ascendis Pharma A/S | $16.9M | 1.8% | +8% | 41.5 |
| 21 |  $UNH | UNITEDHEALTH GROUP INC | $15.7M | 1.6% | +15% | 66.8 |
| 22 |  $DNTH | Dianthus Therapeutics, Inc. /DE/ | $14.4M | 1.5% | +73% | 26.8 |
| 23 |  $ABT | ABBOTT LABORATORIES | $14.4M | 1.5% | NEW | 67 |
| 24 |  $RVMD | Revolution Medicines, Inc. | $13.7M | 1.4% | -7% | — |
| 25 |  $ACHC | Acadia Healthcare Company, Inc. | $13.6M | 1.4% | NEW | 49.3 |
| 26 |  $NEO | NEOGENOMICS INC | $13.2M | 1.4% | +5% | 34.6 |
| 27 |  $COO | COOPER COMPANIES, INC. | $12.1M | 1.3% | +68% | 55.8 |
| 28 |  $NTRA | Natera, Inc. | $12.0M | 1.3% | NEW | 46.4 |
| 29 |  $ITGR | Integer Holdings Corp | $11.9M | 1.3% | +27% | 50.2 |
| 30 |  $RYTM | RHYTHM PHARMACEUTICALS, INC. | $11.9M | 1.3% | +240% | 30.3 |
| 31 |  $WAT | WATERS CORP /DE/ | $11.8M | 1.3% | -8% | 69.9 |
| 32 |  $AMRX | Amneal Pharmaceuticals, Inc. | $11.6M | 1.2% | -37% | 58.9 |
| 33 |  $PRAX | Praxis Precision Medicines, Inc. | $11.4M | 1.2% | +14% | — |
| 34 |  $HSIC | HENRY SCHEIN INC | $11.3M | 1.2% | NEW | 52 |
| 35 |  $CGON | CG Oncology, Inc. | $11.2M | 1.2% | +1% | 28 |
| 36 |  $MMSI | MERIT MEDICAL SYSTEMS INC | $11.2M | 1.2% | NEW | 60.1 |
| 37 |  $CLDX | Celldex Therapeutics, Inc. | $10.3M | 1.1% | +144% | 13.2 |
| 38 |  $BLTE | BELITE BIO, INC | $9.5M | 1.0% | +200% | — |
| 39 |  $DXCM | DEXCOM INC | $9.4M | 1.0% | -34% | 77.9 |
| 40 |  $TERN | Terns Pharmaceuticals, Inc. | $9.1M | 1.0% | NEW | — |
| 41 |  $CNC | CENTENE CORP | $8.6M | 0.9% | -64% | 52.7 |
| 42 |  $VKTX | Viking Therapeutics, Inc. | $8.6M | 0.9% | +39% | — |
| 43 |  $ORKA | Oruka Therapeutics, Inc. | $8.5M | 0.9% | NEW | — |
| 44 |  $TNGX | Tango Therapeutics, Inc. | $8.5M | 0.9% | NEW | 26.9 |
| 45 |  $SLNO | SOLENO THERAPEUTICS INC | $8.3M | 0.9% | +0% | 46.3 |
| 46 |  $BTSG | BrightSpring Health Services, Inc. | $8.0M | 0.8% | +58% | 64.3 |
| 47 |  $CMPS | COMPASS Pathways plc | $7.6M | 0.8% | +75% | — |
| 48 |  $TMO | THERMO FISHER SCIENTIFIC INC. | $7.3M | 0.8% | -61% | 63.7 |
| 49 |  $NVO | NOVO NORDISK A S | $7.2M | 0.8% | NEW | — |
| 50 |  $SYK | STRYKER CORP | $7.2M | 0.8% | -57% | 69.8 |
| 51 |  $VERA | Vera Therapeutics, Inc. | $7.0M | 0.7% | +62% | — |
| 52 |  $BLLN | BillionToOne, Inc. | $7.0M | 0.7% | +1% | — |
| 53 |  $CAH | CARDINAL HEALTH INC | $6.7M | 0.7% | -49% | 58.6 |
| 54 |  $ICLR | ICON PLC | $6.4M | 0.7% | -50% | — |
| 55 |  $ALHC | Alignment Healthcare, Inc. | $6.3M | 0.7% | NEW | 63 |
| 56 |  $HCA | HCA Healthcare, Inc. | $6.3M | 0.7% | -4% | 70.5 |
| 57 |  $GPCR | Structure Therapeutics Inc. | $6.1M | 0.6% | +85% | — |
| 58 |  $ROIV | Roivant Sciences Ltd. | $5.7M | 0.6% | NEW | — |
| 59 |  $OSCR | Oscar Health, Inc. | $5.7M | 0.6% | +0% | 70.4 |
| 60 |  $SNDX | Syndax Pharmaceuticals Inc | $5.7M | 0.6% | +1% | 30 |
| 61 |  $TARS | Tarsus Pharmaceuticals, Inc. | $5.6M | 0.6% | +193% | 40.8 |
| 62 |  $PSNL | Personalis, Inc. | $5.5M | 0.6% | +8% | 15.7 |
| 63 | $ASNDCALL | Ascendis Pharma A/S | $5.1M | — | NEW | 41.5 |
| 64 |  $KOD | Kodiak Sciences Inc. | $4.4M | 0.5% | NEW | — |
| 65 |  $ARWR | ARROWHEAD PHARMACEUTICALS, INC. | $4.0M | 0.4% | NEW | 74.4 |
| 66 |  $EPRX | EUPRAXIA PHARMACEUTICALS INC. | $3.9M | 0.4% | NEW | — |
| 67 |  $DFTX | Definium Therapeutics, Inc. | $3.9M | 0.4% | NEW | — |
| 68 |  $MLYS | Mineralys Therapeutics, Inc. | $3.9M | 0.4% | +200% | — |
| 69 |  $MDLN | Medline Inc. | $3.9M | 0.4% | +2% | — |
| 70 |  $CAPR | CAPRICOR THERAPEUTICS, INC. | $3.8M | 0.4% | NEW | — |
| 71 |  $ILMN | ILLUMINA, INC. | $3.6M | 0.4% | NEW | 62.5 |
| 72 |  $ARGX | ARGENX SE | $3.3M | 0.3% | +8% | — |
| 73 |  $CGEM | Cullinan Therapeutics, Inc. | $3.2M | 0.3% | +0% | — |
| 74 |  $ABVX | Abivax S.A. | $3.0M | 0.3% | -16% | — |
| 75 |  $OM | Outset Medical, Inc. | $2.3M | 0.2% | +12% | 17.6 |
| 76 | $HCAPUT | HCA Healthcare, Inc. | $2.2M | — | NEW | 70.5 |
| 77 |  $MBX | MBX Biosciences, Inc. | $2.1M | 0.2% | -9% | — |
| 78 |  $AMLX | Amylyx Pharmaceuticals, Inc. | $2.0M | 0.2% | +8% | — |
| 79 |  $CRBU | Caribou Biosciences, Inc. | $1.8M | 0.2% | +0% | 6.1 |
| 80 |  $GMED | GLOBUS MEDICAL INC | $1.5M | 0.1% | NEW | 77.6 |
| 81 |  $TECX | Tectonic Therapeutic, Inc. | $1.4M | 0.1% | +8% | — |
| 82 |  $QURE | uniQure N.V. | $697,082 | 0.1% | +8% | — |
| 83 |  $RZLT | Rezolute, Inc. | $392,614 | 0.0% | -38% | — |
New Positions (24)
$UTHRPUT UNITED THERAPEUTICS Corp$27.2M$UTHRCALL UNITED THERAPEUTICS Corp$18.8M$ABT ABBOTT LABORATORIES$14.4M$ACHC Acadia Healthcare Company, Inc.$13.6M$NTRA Natera, Inc.$12.0M$HSIC HENRY SCHEIN INC$11.3M$MMSI MERIT MEDICAL SYSTEMS INC$11.2M$TERN Terns Pharmaceuticals, Inc.$9.1M$ORKA Oruka Therapeutics, Inc.$8.5M$TNGX Tango Therapeutics, Inc.$8.5M$NVO NOVO NORDISK A S$7.2M$ALHC Alignment Healthcare, Inc.$6.3M$ROIV Roivant Sciences Ltd.$5.7MExited Positions (19)
$ADMA ADMA BIOLOGICS, INC.
$MDT Medtronic plc
$MRK Merck & Co., Inc.$CNCCALL CENTENE CORP
$UHS UNIVERSAL HEALTH SERVICES INC
$TFX TELEFLEX INC
$ISRG INTUITIVE SURGICAL INC
$GILD GILEAD SCIENCES, INC.
$CVS CVS HEALTH Corp
$SNY Sanofi
$IQV IQVIA HOLDINGS INC.
$VEEV VEEVA SYSTEMS INC
$ALGN ALIGN TECHNOLOGY INC
$ELAN Elanco Animal Health Inc
$MOH MOLINA HEALTHCARE, INC.Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Partner Fund Management, L.P. including:
Track Partner Fund Management, L.P.'s Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Partner Fund Management, L.P. and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Partner Fund Management, L.P.
13F Pro is an AI hedge fund tracker and stock research platform. For Partner Fund Management, L.P. (SEC CIK: 1442756), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Partner Fund Management, L.P.'s portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.